John P.  Hamill net worth and biography

John Hamill Biography and Net Worth

John P. Hamill, CPA, joined Aprea in January 2023 from Windtree Therapeutics where he served as Senior Vice President and Chief Financial Officer since 2020. He brings more than 30 years of financial leadership experience in the pharmaceutical, biopharmaceutical, and clinical research sectors. He has broad-based experience in financial, administrative, information technology, and facility functions, in addition to having successfully completed IPO and follow-on offerings for several pharmaceutical companies. John has also recently provided consulting services to various life science companies, headed up finance at Trevena, Inc., where he was instrumental in successfully raising equity; NephroGenex, Inc., where he actively led the IPO and subsequent financial restructuring and sale of the company; Savient Pharmaceuticals, where he led a sale process resulting in $120 million in proceeds; and PharmaNet where he successfully completed its sale for approximately $250 million, which then became known as PharmaNet Development Group, where he directed financial and administrative operations for the company. John received a B.S. in Accounting and Business and Computer Science from DeSales University and is a certified public accountant.

What is John P. Hamill's net worth?

The estimated net worth of John P. Hamill is at least $16.81 thousand as of December 10th, 2025. Hamill owns 27,733 shares of Aprea Therapeutics stock worth more than $16,806 as of October 7th. This net worth evaluation does not reflect any other assets that Hamill may own. Learn More about John P. Hamill's net worth.

How do I contact John P. Hamill?

The corporate mailing address for Hamill and other Aprea Therapeutics executives is 3805 Old Easton Road, Doylestown, PA, 18902. Aprea Therapeutics can also be reached via phone at (215) 948-4119 and via email at [email protected]. Learn More on John P. Hamill's contact information.

Has John P. Hamill been buying or selling shares of Aprea Therapeutics?

John P. Hamill has not been actively trading shares of Aprea Therapeutics during the last quarter. Most recently, on Wednesday, December 10th, John P. Hamill bought 5,000 shares of Aprea Therapeutics stock. The stock was acquired at an average cost of $1.17 per share, with a total value of $5,850.00. Following the completion of the transaction, the chief financial officer now directly owns 27,733 shares of the company's stock, valued at $32,447.61. Learn More on John P. Hamill's trading history.

Who are Aprea Therapeutics' active insiders?

Aprea Therapeutics' insider roster includes Lars Abrahmsen (SVP), Eyal Attar (SVP), Marc Duey (Director), Oren Gilad (CEO), John Hamill (CFO), and Gregory Korbel (SVP). Learn More on Aprea Therapeutics' active insiders.

Are insiders buying or selling shares of Aprea Therapeutics?

In the last year, Aprea Therapeutics insiders bought shares 2 times. They purchased a total of 26,459 shares worth more than $30,957.03. The most recent insider tranaction occured on December, 10th when Director Marc Duey bought 21,459 shares worth more than $25,107.03. Insiders at Aprea Therapeutics own 10.5% of the company. Learn More about insider trades at Aprea Therapeutics.

Information on this page was last updated on 12/10/2025.

John P. Hamill Insider Trading History at Aprea Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/10/2025Buy5,000$1.17$5,850.0027,733View SEC Filing Icon  
10/10/2024Buy450$2.61$1,174.5019,318View SEC Filing Icon  
3/13/2024Buy1,010$7.29$7,362.9015,503View SEC Filing Icon  
See Full Table

John P. Hamill Buying and Selling Activity at Aprea Therapeutics

This chart shows John P. Hamill's buying and selling at Aprea Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Aprea Therapeutics Company Overview

Aprea Therapeutics logo
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Read More

Today's Range

Now: $0.61
Low: $0.58
High: $0.64

50 Day Range

MA: $0.73
Low: $0.60
High: $0.98

2 Week Range

Now: $0.61
Low: $0.55
High: $1.69

Volume

248,511 shs

Average Volume

898,562 shs

Market Capitalization

$7.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66